Dr. Gaurav Sharma, of Virtua Health, said more research is needed ... The 39-year-old says he's sober now, and he believes Wegovy is helping him stay that way. "I don't have to fight my brain ...

Wegovy is a weight loss medication that you can only get with a prescription from a licensed healthcare professional. Learn more about who is eligible and what to expect at your initial ...

The diabetes and weight loss medications Ozempic and Wegovy are now considered to be available after more than two years of being considered in shortage by the Food and Drug Administration (FDA).

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds. People taking this class of drugs ...

But as weight loss medications like Ozempic, Wegovy and others become household names, people trying to lose weight are exploring adding medications to their weight loss toolkit. “Obesity is a ...

Few things have stirred up as much commotion in either the weight loss or pharmaceutical world as Ozempic and Wegovy. There's a good reason for that — these drugs have proven to be highly ...

Ozempic (semaglutide) and Wegovy (semaglutide) are prescription drugs that may be used to help with long-term weight loss. But only Wegovy is FDA-approved for this use. Both drugs are approved for ...

Semaglutide, better known as Ozempic and Wegovy, helped alleviate pain from knee osteoarthritis and improve function in patients with severe obesity, a new study found. The results of the 68 ...

It was sometime during the COVID-19 pandemic when Wegovy and Ozempic hit mainstream awareness. Since then, they have taken the weight loss industry by storm. (Also Read | Lose 3 kg in 7 days?

The demand for weight loss operations dropped sharply last year as the number of people opting for anti-obesity drugs such as Wegovy and Saxenda more than doubled, a study published Friday found.

Wegovy may significantly reduce hospital admissions for any cause and overall length of stay, according to a new analysis of data from Novo Nordisk's phase 3 SELECT trial. Compared to patients ...